Solid Biosciences (NASDAQ:SLDB) Stock Rating Upgraded by Cantor Fitzgerald

Cantor Fitzgerald upgraded shares of Solid Biosciences (NASDAQ:SLDB) to a strong-buy rating in a research report report published on Tuesday morning,Zacks.com reports. Cantor Fitzgerald also issued estimates for Solid Biosciences’ FY2025 earnings at ($1.60) EPS.

A number of other equities analysts have also weighed in on SLDB. Chardan Capital restated a “buy” rating and issued a $16.00 target price on shares of Solid Biosciences in a research note on Friday, March 7th. HC Wainwright upped their target price on Solid Biosciences from $16.00 to $20.00 and gave the stock a “buy” rating in a research note on Monday, March 10th. Finally, JPMorgan Chase & Co. decreased their price target on shares of Solid Biosciences from $12.00 to $11.00 and set an “overweight” rating on the stock in a research note on Thursday, March 13th. Eight research analysts have rated the stock with a buy rating and five have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $15.67.

Solid Biosciences Price Performance

NASDAQ:SLDB opened at $2.59 on Tuesday. The company has a market capitalization of $200.73 million, a P/E ratio of -0.85 and a beta of 2.32. The business has a fifty day simple moving average of $3.58 and a two-hundred day simple moving average of $4.24. Solid Biosciences has a 1 year low of $2.41 and a 1 year high of $10.37.

Solid Biosciences (NASDAQ:SLDB) last released its quarterly earnings data on Wednesday, May 21st. The company reported ($0.59) EPS for the quarter, missing the consensus estimate of ($0.53) by ($0.06). As a group, analysts anticipate that Solid Biosciences will post -2.84 earnings per share for the current year.

Institutional Trading of Solid Biosciences

Institutional investors and hedge funds have recently bought and sold shares of the stock. Siren L.L.C. grew its holdings in shares of Solid Biosciences by 97.8% in the first quarter. Siren L.L.C. now owns 7,415,905 shares of the company’s stock valued at $27,439,000 after purchasing an additional 3,666,864 shares in the last quarter. Vestal Point Capital LP raised its position in shares of Solid Biosciences by 1.8% during the 4th quarter. Vestal Point Capital LP now owns 2,850,000 shares of the company’s stock valued at $11,400,000 after buying an additional 50,000 shares in the last quarter. Redmile Group LLC lifted its holdings in shares of Solid Biosciences by 228.2% in the 1st quarter. Redmile Group LLC now owns 2,019,171 shares of the company’s stock valued at $7,471,000 after acquiring an additional 1,403,925 shares during the last quarter. Monashee Investment Management LLC grew its position in Solid Biosciences by 248.6% in the first quarter. Monashee Investment Management LLC now owns 1,673,412 shares of the company’s stock worth $6,192,000 after acquiring an additional 1,193,412 shares in the last quarter. Finally, MPM Bioimpact LLC purchased a new position in Solid Biosciences in the first quarter worth about $6,077,000. 81.46% of the stock is currently owned by institutional investors.

Solid Biosciences Company Profile

Solid Biosciences Inc, a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia.